216 related articles for article (PubMed ID: 32704112)
41. Geniposide inhibits proliferation and induces apoptosis of diffuse large B-cell lymphoma cells by inactivating the HCP5/miR-27b-3p/MET axis.
Hu L; Zhao J; Liu Y; Liu X; Lu Q; Zeng Z; Zhu L; Tong X; Xu Q
Int J Med Sci; 2020; 17(17):2735-2743. PubMed ID: 33162801
[TBL] [Abstract][Full Text] [Related]
42. Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far.
Castillo JJ; Beltran BE; Miranda RN; Paydas S; Winer ES; Butera JN
Oncologist; 2011; 16(1):87-96. PubMed ID: 21212426
[TBL] [Abstract][Full Text] [Related]
43. Reappraisal of Epstein-Barr virus (EBV) in diffuse large B-cell lymphoma (DLBCL): comparative analysis between EBV-positive and EBV-negative DLBCL with EBV-positive bystander cells.
Ohashi A; Kato S; Okamoto A; Inaguma Y; Satou A; Tsuzuki T; Emi N; Okamoto M; Nakamura S
Histopathology; 2017 Jul; 71(1):89-97. PubMed ID: 28231401
[TBL] [Abstract][Full Text] [Related]
44. MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma.
Shi JQ; Lasky K; Shinde V; Stringer B; Qian MG; Liao D; Liu R; Driscoll D; Nestor MT; Amidon BS; Rao Y; Duffey MO; Manfredi MG; Vos TJ; D' Amore N; Hyer ML
Mol Cancer Ther; 2012 Sep; 11(9):2045-53. PubMed ID: 22609854
[TBL] [Abstract][Full Text] [Related]
45. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ
Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088
[TBL] [Abstract][Full Text] [Related]
46. ON 01910.Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex.
Dai YH; Hung LY; Chen RY; Lai CH; Chang KC
Transl Res; 2016 Sep; 175():129-143.e13. PubMed ID: 27150054
[TBL] [Abstract][Full Text] [Related]
47. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
[TBL] [Abstract][Full Text] [Related]
48. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.
Klanova M; Andera L; Brazina J; Svadlenka J; Benesova S; Soukup J; Prukova D; Vejmelkova D; Jaksa R; Helman K; Vockova P; Lateckova L; Molinsky J; Maswabi BC; Alam M; Kodet R; Pytlik R; Trneny M; Klener P
Clin Cancer Res; 2016 Mar; 22(5):1138-49. PubMed ID: 26467384
[TBL] [Abstract][Full Text] [Related]
49. Long non-coding RNA SNHG16 promotes proliferation and inhibits apoptosis of diffuse large B-cell lymphoma cells by targeting miR-497-5p/PIM1 axis.
Zhu Q; Li Y; Guo Y; Hu L; Xiao Z; Liu X; Wang J; Xu Q; Tong X
J Cell Mol Med; 2019 Nov; 23(11):7395-7405. PubMed ID: 31483572
[TBL] [Abstract][Full Text] [Related]
50. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
51. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
52. Tumor cell-expressed IL-15Rα drives antagonistic effects on the progression and immune control of gastric cancer and is epigenetically regulated in EBV-positive gastric cancer.
Wei J; Guo C; An X; Miao W; Zhang C; Wang B; Cai W; Li M; Zhang F
Cell Oncol (Dordr); 2020 Dec; 43(6):1085-1097. PubMed ID: 32767257
[TBL] [Abstract][Full Text] [Related]
53. Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth
Anastasiadou E; Seto AG; Beatty X; Hermreck M; Gilles ME; Stroopinsky D; Pinter-Brown LC; Pestano L; Marchese C; Avigan D; Trivedi P; Escolar DM; Jackson AL; Slack FJ
Clin Cancer Res; 2021 Feb; 27(4):1139-1149. PubMed ID: 33208342
[TBL] [Abstract][Full Text] [Related]
54. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma.
Pham LV; Bryant JL; Mendez R; Chen J; Tamayo AT; Xu-Monette ZY; Young KH; Manyam GC; Yang D; Medeiros LJ; Ford RJ
Oncotarget; 2016 Dec; 7(49):80599-80611. PubMed ID: 27716624
[TBL] [Abstract][Full Text] [Related]
55. The tumor suppressive role of inhibin βA in diffuse large B-cell lymphoma.
Jiang L; Si T; Yu M; Zeng X; Morse HC; Lu Y; Ouyang G; Zhou JX
Leuk Lymphoma; 2018 May; 59(5):1202-1212. PubMed ID: 28877610
[TBL] [Abstract][Full Text] [Related]
56. High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma.
Carreras J; Kikuti YY; Hiraiwa S; Miyaoka M; Tomita S; Ikoma H; Ito A; Kondo Y; Itoh J; Roncador G; Martinez A; Colomo L; Hamoudi R; Ando K; Nakamura N
Cancer Sci; 2022 Jan; 113(1):334-348. PubMed ID: 34706126
[TBL] [Abstract][Full Text] [Related]
57. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro.
Quan L; Chen X; Liu A; Zhang Y; Guo X; Yan S; Liu Y
PLoS One; 2015; 10(9):e0136476. PubMed ID: 26361042
[TBL] [Abstract][Full Text] [Related]
58. CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival.
Moreno MJ; Bosch R; Dieguez-Gonzalez R; Novelli S; Mozos A; Gallardo A; Pavón MÁ; Céspedes MV; Grañena A; Alcoceba M; Blanco O; Gonzalez-Díaz M; Sierra J; Mangues R; Casanova I
J Pathol; 2015 Feb; 235(3):445-55. PubMed ID: 25231113
[TBL] [Abstract][Full Text] [Related]
59. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
[No Abstract] [Full Text] [Related]
60. A novel silicone derivative of natural osalmid (DCZ0858) induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma via the JAK2/STAT3 pathway.
Lu K; Li B; Zhang H; Xu Z; Song D; Gao L; Sun H; Li L; Wang Y; Feng Q; Chen G; Hu L; Wei R; Xie Y; Yu D; Wu X; Zhu W; Shi J
Signal Transduct Target Ther; 2020 Apr; 5(1):31. PubMed ID: 32296013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]